+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Vein-to-Vein Cell and Gene Therapy (CGT) Cryogenic Couriers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 150 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294067
The vein-to-vein cell and gene therapy cryogenic couriers market size is valued at USD 0.84 billion in 2026 and is estimated to reach USD 0.94 billion in 2027 and USD 1.48 billion by 2032, registering a CAGR of 9.61% from 2027 to 2032. This report is Segmented by Therapy Type (Autologous, and More), by Shipment Stage (Patient-Derived/Donor-Derived, and More), by Destination (Domestic, International), by Mode of Transport (Air, Road, Others), by End User (Biopharma, and More), and by Geography (North America, South America, Europe, Asia-Pacific, MEA). The Market Forecasts are Provided in Value (USD).

Global Vein-to-Vein Cell and Gene Therapy (CGT) Cryogenic Couriers Market Trends and Insights

Expansion of Approved and Late-Stage Cell and Gene Therapy Pipelines

The vein-to-vein cell and gene therapy cryogenic couriers market gains recurring demand when a therapy moves from development into commercial use. There were 59 gene therapy programs in Phase III globally in Q2 2026, compared with 45 in Q2 2025. PhRMA documented 438 cell and gene therapies in active United States development in March 2026, and reported that China had surpassed the United States in global trial activity after its share of global trials grew by 15% since 2019. Each approval creates a continuing need to move patient material or released product under controlled conditions. FDA requirements for cellular and gene therapy products place strong importance on validated handling, temperature management, and documented custody. That framework favors providers with qualified cryogenic equipment and established compliance processes.

Growth of Autologous and Allogeneic Treatment Volumes

Treatment volumes are increasing as the approved roster of cellular and gene therapy products expands. The FDA list includes recent products such as AUCATZYL, TREGZI, OTARMENI, PAPZIMEOS, and ZEVASKYN. The Alliance for Regenerative Medicine identified a possible first CAR-T regulatory submission for Stiff Person Syndrome in the first half of 2026, extending the potential use of CAR-T therapies beyond oncology. Each autologous treatment creates a collection shipment and a return shipment of the finished product. Allogeneic treatment uses donor material and supports production at a larger scale, but it needs reliable hub-and-spoke cryogenic networks. ICH identifies donor-to-recipient traceability as a key consideration for advanced therapy medicinal products. These treatment models require different operations, yet both expand the need for qualified custody and transport services.

High Cost and Limited Availability of Qualified Cryogenic Infrastructure

Cryogenic depots, liquid nitrogen tanks, controlled-temperature rooms, dry vapor shippers, and airport staging facilities remain concentrated in a limited number of North American and European cities. Establishing a new depot requires capital, equipment qualification, and compliance with local rules before it can handle clinical or commercial materials. This can leave new therapy locations without suitable local capacity when launches proceed faster than infrastructure development. A May 2025 ISCT survey identified scaling cryopreservation as the most frequently cited operating hurdle among organizations supporting therapy commercialization. The vein-to-vein cell and gene therapy cryogenic couriers market is, therefore, constrained by more than vehicle or flight availability. It also depends on qualified sites, trained operators, standardized procedures, and sufficient liquid nitrogen support near collection and treatment locations.

Other drivers and restraints analyzed in the detailed report include:

  1. Rising Need for Patient-Specific Chain-of-Identity Assurance
  2. Growth of Global Clinical Trials and Cross-Border Therapy Distribution
  3. Air-Cargo, Dangerous-Goods, and Customs Restrictions

Segment Analysis

Autologous cell therapies held 47.31% of the vein-to-vein cell and gene therapy cryogenic couriers market share in 2026, reflecting their leading role among commercialized patient-specific products. Their position is linked to a one-to-one relationship between a patient's collected cells and the dose returned for infusion. Each treatment cycle creates at least 2 cryogenic shipment events, covering upstream material collection and downstream return of the finished therapy. These movements need clear scheduling between collection centers, manufacturing sites, quality-release teams, and infusion locations. That operating design means a rise in autologous treatment volumes creates a corresponding need for qualified courier capacity. Three programs, avigbagene parvec, KITE-753, and TAEST-16001, entered Phase III in Q2 2026. Their progress illustrates how late-stage development can extend demand beyond the current base of commercial therapies. Gene therapy shipments also need validated temperature conditions, clear custody documentation, and reliable transfer between specialized facilities. Together, the two therapy types place different but sustained demands on the cell and gene therapy cryogenic couriers market.

Gene therapies registered a CAGR of 13.27% through 2032, the fastest rate among therapy-type segments. Allogeneic cell therapies use donor-derived starting material and follow a different logistics model from autologous products. Production can be undertaken at larger scale, with inventory held in qualified cryogenic depots before allocation to eligible patients. This shifts operational emphasis toward inventory control, lot-to-patient allocation, and dependable hub-and-spoke distribution. Couriers, therefore, need to support both individual identity continuity and disciplined control of larger cryogenic inventory pools. ISO 21973:2020 provides an international benchmark for the transportation of cells for therapeutic use. Cryoport reported ISO 21973:2020 certification in 2025, showing that recognized transport standards were becoming a relevant competitive requirement. Other cryogenically transported CGT products include exosome-based therapeutics and gene-modified tissue products. These early-stage modalities have requirements that are still being formalized across development, transport, and clinical use. Their progress may require providers to adapt qualification practices while retaining strict temperature and documentation controls. This variety of therapy models increases the need for flexible but standardized cryogenic operations.

Finished therapeutic products accounted for 45.65% of the vein-to-vein cell and gene therapy cryogenic couriers market size in 2026. These shipments carry released CAR-T and gene therapy products from manufacturing sites to qualified infusion centers. The segment reflects the present weight of approved therapies that require recurring patient-level deliveries. Released products are high-value and often need detailed records for temperature, location, handoff, and delivery condition. Delivery timing also has to align with the receiving center's preparation for the patient. This faster rate reflects rising collection activity as clinical programs broaden and more treatments move toward commercialization. Starting-material movements depend on apheresis coordination, collection-site readiness, packaging, and timely manufacturing-site receipt. A weak handoff at this early stage can affect the entire treatment sequence. The faster expansion of upstream shipments creates a larger role for courier coordination before manufacturing begins.

Patient-derived and donor-derived starting materials registered a CAGR of 11.83% through 2032. In-process materials form a third shipment stage between testing organizations, manufacturing steps, and release sites. These transfers often occur within a distributed manufacturing network that includes specialist analytical, processing, and quality functions. Each movement has to preserve material identity and establish a documented connection between the sending and receiving sites. FDA and EMA expectations for biological products reinforce the use of validated processes for site-to-site handling. The cell and gene therapy cryogenic couriers market supports these links by maintaining qualified conditions across transfers that cannot be handled through conventional freight processes. The shift toward starting materials shows that logistics intensity is moving earlier in the therapy pathway. Collection networks will need closer coordination with manufacturing schedules as patient volume rises. CDMO outsourcing adds further transfers among facilities and makes standardized custody procedures more important. Finished products will retain their leading position in 2026, while upstream activity will place growing demands on qualified courier networks. This balance explains why stage-specific planning is central to vein-to-vein logistics.

Complete Report Scope:

  • By Therapy Type
    • Autologous Cell Therapies
    • Allogeneic Cell Therapies
    • Gene Therapies
    • Other Cryogenically Transported CGT Products
  • By Shipment Stage
    • Patient-Derived / Donor-Derived Starting Materials
    • Intermediate / In-Process Materials
    • Finished Therapeutic Products
  • By Destination
    • Domestic
    • International
  • By Mode of Transport
    • Air
    • Road
    • Others
  • By End User
    • Biopharmaceutical and Biotechnology Companies
    • Contract Development and Manufacturing Organizations
    • Hospitals and Treatment Centers
    • Academic and Research Institutions
    • Other Healthcare and Life Sciences Organizations
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Peru
      • Chile
      • Rest of South America
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Russia
      • Nordics (Denmark, Finland, Iceland, Norway, and Sweden)
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Southeast Asia (ASEAN)
      • Rest of Asia-Pacific
    • Middle East and Africa
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • South Africa
      • Nigeria
      • Egypt
      • Rest of Middle East and Africa

Geography Analysis

North America accounted for 42.26% of the vein-to-vein cell and gene therapy cryogenic couriers market share in 2026. The region has the largest base of approved CGT products, substantial CDMO capacity, and established regulatory processes for these treatments. FDA expectations for shipping validation, cold-chain documentation, and temperature excursion reporting support demand for specialized providers. The Alliance for Regenerative Medicine recorded 6 new United States CGT drug approvals during 2025 and identified 10 or more possible regulatory submissions in 2026. Canada adds growth through active clinical sites and approved treatment centers.

Europe holds the second-largest regional position in 2026, supported by ATMP activity across Germany, the United Kingdom, France, and the Nordic countries. The EMA ATMP framework and GDP requirements place high qualification requirements on cryogenic depots and transport lanes. These requirements limit participation to providers that can document compliant handling. Cencora added NextPharma Logistics in December 2025, expanding its GDP-compliant presence across Germany, Austria, and Switzerland. Lonza expanded logistics capacity at its Porrino site in Spain in October 2025, reinforcing the connection between regional manufacturing investment and local courier demand. South America, the Middle East and Africa, and Russia represent smaller positions, while Brazil and the United Arab Emirates are emerging locations for clinical access and advanced therapy activity.

Asia-Pacific registered a CAGR of 12.95% through 2032, the fastest regional rate in the vein-to-vein cell and gene therapy cryogenic couriers market. China has increased its share of global CGT trials, while South Korea and Japan are progressing in domestic cell therapy commercialization. Qualified cryogenic depots remain scarce outside key gateway cities, which increases the value of targeted local investment. World Courier expanded its cryogenic depot network with new facilities in Beijing and Sao Paulo in 2025. Country-level import procedures, containment requirements, and local GDP standards can add cost and complexity to shipments within the region. These conditions create a need for providers with both regional infrastructure and strong local regulatory knowledge.



List of Companies Covered in this Report:

  1. Cryoport, Inc.
  2. DHL Group
  3. La Poste Group (Including Biocair)
  4. Cencora, Inc.
  5. United Parcel Service of America, Inc. (UPS)
  6. FedEx
  7. AIT Worldwide Logistics
  8. Kuehne+Nagel
  9. BioLife Solutions, Inc.
  10. Thermo Fisher Scientific Inc.
  11. Lonza Group Ltd.
  12. TrakCel Limited
  13. Envirotainer AB
  14. Mercury
  15. World Distribution Services
  16. Aramex
  17. Expeditors International of Washington, Inc.
  18. A.P. Moller-Maersk
  19. Modality Solutions
  20. SkyCell

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expansion of Approved and Late-Stage Cell and Gene Therapy Pipelines
4.2.2 Growth of Autologous and Allogeneic Treatment Volumes
4.2.3 Rising Need for Patient-Specific Chain-of-Identity Assurance
4.2.4 Growth of Global Clinical Trials and Cross-Border Therapy Distribution
4.2.5 Increasing Adoption of Digital Control Towers and Real-Time Monitoring
4.2.6 Regional Cryogenic Hub Build-Out for Shorter Vein-to-Vein Time
4.3 Market Restraints
4.3.1 High Cost and Limited Availability of Qualified Cryogenic Infrastructure
4.3.2 Air-Cargo, Dangerous-Goods and Customs Restrictions
4.3.3 Unpredictable Liquid-Nitrogen Hold Time and Shipper-Handling Risk
4.3.4 Scarcity of Trained Personnel and Standardized Cross-Partner Procedures
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
4.8 Impact of Geopolitical Events on the Market
5 Market Size and Growth Forecasts (Value in USD)
5.1 By Therapy Type
5.1.1 Autologous Cell Therapies
5.1.2 Allogeneic Cell Therapies
5.1.3 Gene Therapies
5.1.4 Other Cryogenically Transported CGT Products
5.2 By Shipment Stage
5.2.1 Patient-Derived / Donor-Derived Starting Materials
5.2.2 Intermediate / In-Process Materials
5.2.3 Finished Therapeutic Products
5.3 By Destination
5.3.1 Domestic
5.3.2 International
5.4 By Mode of Transport
5.4.1 Air
5.4.2 Road
5.4.3 Others
5.5 By End User
5.5.1 Biopharmaceutical and Biotechnology Companies
5.5.2 Contract Development and Manufacturing Organizations
5.5.3 Hospitals and Treatment Centers
5.5.4 Academic and Research Institutions
5.5.5 Other Healthcare and Life Sciences Organizations
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 South America
5.6.2.1 Brazil
5.6.2.2 Argentina
5.6.2.3 Peru
5.6.2.4 Chile
5.6.2.5 Rest of South America
5.6.3 Europe
5.6.3.1 Germany
5.6.3.2 United Kingdom
5.6.3.3 France
5.6.3.4 Italy
5.6.3.5 Spain
5.6.3.6 Russia
5.6.3.7 Nordics (Denmark, Finland, Iceland, Norway, and Sweden)
5.6.3.8 Rest of Europe
5.6.4 Asia-Pacific
5.6.4.1 China
5.6.4.2 India
5.6.4.3 Japan
5.6.4.4 South Korea
5.6.4.5 Australia
5.6.4.6 Southeast Asia (ASEAN)
5.6.4.7 Rest of Asia-Pacific
5.6.5 Middle East and Africa
5.6.5.1 Saudi Arabia
5.6.5.2 United Arab Emirates
5.6.5.3 Qatar
5.6.5.4 South Africa
5.6.5.5 Nigeria
5.6.5.6 Egypt
5.6.5.7 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Key Strategic Moves in the Market
6.3 Market Share Analysis
6.4 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Geographic/Network Coverage, Products and Services, Recent Developments)
6.4.1 Cryoport, Inc.
6.4.2 DHL Group
6.4.3 La Poste Group (Including Biocair)
6.4.4 Cencora, Inc.
6.4.5 United Parcel Service of America, Inc. (UPS)
6.4.6 FedEx
6.4.7 AIT Worldwide Logistics
6.4.8 Kuehne+Nagel
6.4.9 BioLife Solutions, Inc.
6.4.10 Thermo Fisher Scientific Inc.
6.4.11 Lonza Group Ltd.
6.4.12 TrakCel Limited
6.4.13 Envirotainer AB
6.4.14 Mercury
6.4.15 World Distribution Services
6.4.16 Aramex
6.4.17 Expeditors International of Washington, Inc.
6.4.18 A.P. Moller-Maersk
6.4.19 Modality Solutions
6.4.20 SkyCell
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment
7.2 Future Outlook of the Market

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Cryoport, Inc.
  • DHL Group
  • La Poste Group (Including Biocair)
  • Cencora, Inc.
  • United Parcel Service of America, Inc. (UPS)
  • FedEx
  • AIT Worldwide Logistics
  • Kuehne+Nagel
  • BioLife Solutions, Inc.
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • TrakCel Limited
  • Envirotainer AB
  • Mercury
  • World Distribution Services
  • Aramex
  • Expeditors International of Washington, Inc.
  • A.P. Moller-Maersk
  • Modality Solutions
  • SkyCell